The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
<< First    < Prev 10    11 to 20 of 2223    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

Primary site/Unknown and ill-defined site--Melanoma:  What is the primary site for a case of metastatic melanoma with an unknown primary site? See Discussion.

Final Oct 02 2020

Surgery of Primary Site/Multiple primaries--Breast: Should the Surgery of Primary Site for the 2020 diagnosis be coded 51 (Modified radical mastectomy without removal of uninvolved contralateral breast) when a partial mastectomy and axillary lymph node dissection are performed for a 2011 right breast primary and a subsequent 2020 right breast primary is treated with a total mastectomy only? See Discussion.

Final Oct 02 2020

Summary Stage 2018/EOD 2018--Lymphoma Orbital Adnexa:  What is the correct Summary Stage 2018 (SS2018) for the site/histology Orbit, NOS (C696), 9699/3?  In SEER*RSA, Extent of Disease (EOD) Primary Tumor references code 7 (Distant), whereas SS2018 assigns code 2 (Regional)?  See Discussion.

Final Sep 28 2020

Solid Tumor Rules/Multiple Primaries--Lung: How many primaries are accessioned when a patient is diagnosed with right lower lobe invasive acinar adenocarcinoma (8551/3) in 2018 and treated with lobectomy, followed by a 2019 right middle lobe cancer (NOS, 8000/3) diagnosed as new stage 1 primary by cancer conference? See Discussion.

Final Sep 17 2020

Stage-related Data Item/Lymphovascular Invasion--Ovary:  The 2018 SEER Program Coding and Staging Manual states that LVI is coded 8 (Not applicable) for Ovary (Schema 00551). What is the reason for having lymphovascular invasion (LVI) coded "8" for Ovary?  See Discussion.

Final Sep 04 2020

Reportability--Vulva: Is well differentiated vulvar intraepithelial neoplasm (dVIN) reportable? See Discussion.

Final Aug 31 2020

Diagnostic confirmation--Heme & Lymphoid Neoplasms: Is Diagnostic Confirmation coded to 5 or 8 based on a patient diagnosed as multiple myeloma by a physician based on a bone marrow biopsy stating plasma cell neoplasm? See Discussion.

Final Aug 26 2020

Reportability/Histology--Eye: Is conjunctival intraepithelial neoplasia, moderate to severe, reportable and if so, what are the histology and behavior codes? See Discussion.

Final Aug 26 2020

Histology/Behavior--Bladder:  Is the behavior of a bladder tumor with low-grade papillary urothelial carcinoma /2 or /3? See Discussion.

Final Aug 26 2020

Solid Tumor Rules (2018)/Histology--Brain and CNS: How is the histology coded when the diagnosis comment for a posterior fossa tumor resection states:  Taken together, these findings are indicative of medulloblastoma with extensive nodularity? See Discussion.

Final Aug 25 2020
< Prev 10    Next 10 >